Victor Dixon has been appointed vice president and general manager for the printed components business of Catalent Pharma Solutions' Packaging Services segment. Mr. Dixon will be located at the company’s facility in Philadelphia, PA.

Mr. Dixon has in-depth experience and a strong track record of success in packaging and printing. He joins the company from Cortegra Group, a packaging manufacturer, where he was president and chief executive officer. Prior to that, he spent 10 years at Alcoa, Inc. in positions of increasing responsibility, serving as general manager, vice president and general manager and vice president global sales for the Flexible Packaging business.

“Catalent has been fortunate to recruit Victor Dixon. His extensive knowledge of the industry and strong commercial planning skills will enable him to contribute significantly to our success,” said Tracy Tsuetaki, group president, Packaging Services for Catalent.

Johnson & Johnson

2Q Revenues: $16.5 billion (+9%)
2Q Earnings: $3.3 billion (+8%)
YTD Revenues: $32.6 billion (+8%)
YTD Earnings: $6.9 billion (+23%)

Comments: Pharmaceutical sales were $6.3 billion (+3%), driven by Topamax sales ($677 million up 17%), Velcade sales ($205 million up 63%), Risperdal Consta sales ($343 million up 23%), and Remicade sales ($886 million up 2%). Growth was negatively impacted by lower sales of anemia drug Procrit, down 14% to $652 million, due to a decline in the market, and Risperdal Oral sales, down 16% to $712 million, due to generic competition outside the U.S. Companywide international sales were $8.2 billion (+16%), while U.S. sales were $8.2 billion (+2%). Medical devices and diagnostics sales were up 12% to $6.1 billion and consumer sales were up 13% to $4.0 billion. In the quarter, Evolence was FDA-approved for the correction of moderate to deep facial wrinkles and folds and Concerta was approved for the treatment of ADHD in adults.

Genentech
2Q Revenues: $3.2 billion (+7%)
2Q Earnings: $782 million (+5%)
YTD Revenues: $6.3 billion (+7%)
YTD Earnings: $1.8 billion (+21%)
Comments: Rituxan sales were $651 million in the quarter (+12%). Avastin sales were $650 million (+15%). Herceptin sales were $338 million (+3%). Tarceva sales were $119 million (+17%). Sales in the market reached $2.4 billion (+9%). Royalty revenue in the quarter was up 30% to $629 million primarily due to growth in ex-U.S. sales of the company's products by collaborators and foreign exchange benefits of the weak dollar. R&D expenses in the quarter were $649 million (+8%), or 20% of operating revenue.